The deal is expected to close in the second half of 2020, but one analyst expects the transaction will raise antitrust issues in the United States.
Overall activity in deals jumped 11% in North America.
The deal boosts 3M’s capabilities in advanced and surgical wound care.
The strategic acquisitions expand the company’s structural heart disease technologies.
The deal will help J&J speed up its entry into the robotics market.
The deal will help strengthen the Edwards portfolio of smart monitoring technologies.
The $701-million deal is expected to enhance Stryker’s cross-specialty surgical visualization for surgeons.
The union will strengthen BD’s leadership in medication management and infection prevention, and increase opportunities in fast-growing clinical areas and OUS markets.
Medtronic will keep its respiratory and monitoring solutions business, while Cardinal will buy the patient care, DVT, and nutritional insufficiency businesses.
The $435-million deal is part of the company’s commitment to being a leader in products for transcatheter aortic valve implantation.